Accepted at 3:40 p.m. Oct, 31, 2023 by Joe
Author: all001
Related Note: 1474059954350
Rationale for change

Updated terminology

Text Text
Extra Extra
Lecture Notes
Empty field
Missed Questions
Empty field
Pathoma
Empty field
Boards and Beyond
Empty field
First Aid
Empty field
Sketchy
Sketchy 2
Sketchy Extra
Empty field
Picmonic
Empty field
Pixorize
Empty field
Physeo
Bootcamp
OME
Additional Resources
Empty field
One by one
Empty field
#AK_Other::#AK_Original_Decks::Step_1::Zanki_Step_Decks::Zanki_Hematology_&_Oncology::Pathoma_Hematology #AK_Step1_v12::#NinjaNerd::09_Hematology::02_Pathology::15_Antiplatelets,_Anticoagulants,_and_Thrombolytics #AK_Step1_v12::#OME::Clinical::Internal_Medicine::Hematology-Oncology::Approach_To_Bleeding #AK_Step3_v12::#UWorld::5292 #AK_Other::AnKing_Image::!Subjects::Hematology_and_Oncology::Heparin_Induced_Thrombocytopenia #AK_Step1_v12::#Physeo::^physeo_image_update #AK_Step2_v12::#AMBOSS::7T04H2 #AK_Step1_v12::#SketchyPath::09_Blood_&_Coagulation::03_Coagulopathies_&_Platelet_Disorders::01_Quantitative_Platelet_Disorders #AK_Step2_v12::#CMS::Surgery::Form_06 #AK_Step1_v12::#NinjaNerd::09_Hematology::02_Pathology::17_Hypercoagulable_States #AK_Step1_v12::#FirstAid::10_Hematology_and_Oncology::04_Pathology::17_Platelet_disorders::*Heparin_Induced_Thrombocytopenia #AK_Other::AnKing_Image::!Subjects::Hematology_&_Oncology::Heparin_Induced_Thrombocytopenia #AK_Step1_v12::#NinjaNerd::09_Hematology::02_Pathology::18_Coagulopathy #AK_Step1_v12::#Pathoma::04_Hemostasis::03_Other_Disorders_of_Hemostasis #AK_Step1_v12::#NinjaNerd::09_Hematology::02_Pathology::19_Platelet_Disorders #PANCE::HEME::coagulation_disorders #AK_Step1_v12::#B&B::12_Hematology::01_Hemostasis::07_Anticoagulant_Drugs #AK_Step2_v12::#FirstAid::07_Hematology::02_Hypercoagulable_States::03_Heparin-Induced_Thrombocytopenia_(HIT) #AK_Step1_v12::#Bootcamp::Hematology_and_Oncology::07_Coagulation_and_Fibrinolysis::10_Anticoagulation #AK_Step1_v12::#UWorld::COMLEX::26114 #AK_Step1_v12::#AMBOSS::OB0Iai #AK_Other::AnKing_Image::AhmedA::Heparin_Induced_Thrombocytopenia #AK_Step1_v12::#NBME::18 #AK_Step2_v12::#AMBOSS::uT0ps2 #AK_Step1_v12::#AMBOSS::z4arNk #AK_Step2_v12::#SketchyIM::01_Cardiology::05_Blood_Vessel_Disease::01_DVT_SOAP #AK_Step1_v12::#NBME::20 #AK_Step2_v12::#UWorld::Step::6993 #AK_Step1_v12::#UWorld::Step::15120 #AK_Other::AnKing_Image::!Subjects::Hematology_&_Oncology #AK_Step2_v12::#NBME::Form13::Section_4 #AK_Step1_v12::^Systems::HemeOnc::Hematology #AK_Step2_v12::#AMBOSS::Bx0zAR #AK_Step1_v12::#NinjaNerd::06_Cardiovascular::04_Pharmacology::03_Heparin_(MOA,_Indications,_ADR,_CI) #AK_Other::Only_Step_1&2_Overlap #AK_Step1_v12::#Low/HighYield::2-RelativelyHighYield #AK_Step1_v12::#Physeo::11_Pathology::10_HemeOnc_Pathology::03_HIT_DIC_Disorders_of_Fibrinolysis #AK_Step1_v12::#B&B::12_Hematology::01_Hemostasis::02_Platelet_Activation #AK_Step1_v12::#NinjaNerd::04_Pharmacology::01_Basics::03_Antiplatelet,_Anticoagulant,_Thrombolytic_Agents #AK_Step2_v12::#B&B::07_Hematology_and_Oncology::02_Coagulation::05_Anticoagulants #AK_Step2_v12::#UWorld::COMLEX::101730